KDM5B expression in cisplatin resistant neuroblastoma cell lines
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10448286" target="_blank" >RIV/00064203:_____/22:10448286 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/22:10448286
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Gv60qlVa1k" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Gv60qlVa1k</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/ol.2022.13485" target="_blank" >10.3892/ol.2022.13485</a>
Alternative languages
Result language
angličtina
Original language name
KDM5B expression in cisplatin resistant neuroblastoma cell lines
Original language description
Chemoresistance is a major problem in successful cancer therapy. Lysine-specific demethylase 5B (KDM5B), is a member of the KDM5 family of histone demethylases, whose dysregulation has been observed in numerous types of cancer and plays a role in drug tolerance. The present study examined KDM5B expression in high risk neuroblastoma cell lines. Its level was markedly reduced in cisplatin-resistant cells, UKF-NB-4CDDP, compared with parental sensitive cells UKF-NB-4. Moreover, KDM5B-silencing did not affect either viability nor the response to CDDP in resistant cells, and led to increase of proliferation and migration in CDDP resistant cells but not in sensitive ones. Compliant with these results, short interfering KDM5B transfection resulted in increased S phase in resistant cells. Overall, these findings suggested that KDM5B may be involved in the survival mechanisms of neuroblastoma cells, which makes KDM5B a promising factor for the prediction of sensitivity to CDDP that should therefore be considered for future research.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Oncology Letters
ISSN
1792-1074
e-ISSN
—
Volume of the periodical
24
Issue of the periodical within the volume
4
Country of publishing house
GR - GREECE
Number of pages
8
Pages from-to
365
UT code for WoS article
000861142000001
EID of the result in the Scopus database
2-s2.0-85138118874